Britain and America have announced a major bilateral deal that will preserve zero import taxes on British drug products entering the American market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to boost expenditure on drugs through the public health system. This move ensures that duties on these vital exports will be held at nothing for a timeframe of three years.
This development follows recent statements to dramatically increase tariffs on patented pharmaceutical imports, with increases floated up to double the cost.
"This agreement with the Britain reinforces the international landscape for cutting-edge drugs and establishes long-overdue fairness to U.S.–U.K. pharmaceutical trade," a release noted.
Commercial Importance
Medicines are one of the UK's biggest exports to the America, which is by far the biggest buyer for leading British pharmaceutical firms.
Statistics reveal that in the one-year period to the end of the third quarter, the UK exported pharmaceutical products worth billions to the US. This amount accounted for a significant portion of all goods exports in that timeframe.
"This deal secures work, increases funding and facilitates the UK to become a international leader for life sciences," a minister commented.
Specific UK Commitments
The pact includes several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to increase total public funding on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount manufacturers must pay back to the NHS to stay within budget will be capped at fifteen percent. Previously, rebates topped twenty percent.
Industry Background
The deal follows a protracted tension between the sector and the UK government over drug pricing and NHS adoption.
The disagreement were exacerbated by claims that American customers were paying a premium for the equivalent treatments than consumers in the UK and Europe.
In recent months, several major drug company projects in the UK have been paused or cancelled, while substantial investments have been announced toward US facilities.
One official acknowledged that the NHS needed to spend more on medicines, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the previous ten-year period.
